← Leaderboards
Monica J Roth
Rutgers Biomedical And Health Sciences
$14,970,765
Attributed
$14,970,765
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,970,765 · 10
By mechanism
R01$9,377,491 · 7
R35$4,847,924 · 1
R21$745,350 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralProteinsVirusComplexStructureBaseResearch StudyVectorMurine Leukemia VirusSiteCellsGene DeliveryParticleIntegraseGenesAreaLaboratoriesSafetyPreferenceDesignPathogenesisRetroviral VectorMitosisLink
Grant awards (54)
Interactions of retroviral and host proteins guided by advanced modeling$628,000
R35 · FY2025 · GM · contact PI
Interactions of retroviral and host proteins guided by advanced modeling$628,000
R35 · FY2024 · GM · contact PI
Targeting retroviral and virus-like particles for gene and protein delivery$26,599
R35 · FY2024 · GM · contact PI
Interactions of retroviral and host proteins guided by advanced modeling$644,288
R35 · FY2023 · GM · contact PI
Targeting retroviral and virus-like particles for gene and protein delivery$630,341
R35 · FY2021 · GM · contact PI
Targeting retroviral and virus-like particles for gene and protein delivery$630,341
R35 · FY2020 · GM · contact PI
Targeting retroviral and virus-like particles for gene and protein delivery$630,341
R35 · FY2019 · GM · contact PI
Targeting retroviral and virus-like particles for gene and protein delivery$66,982
R35 · FY2019 · GM · contact PI
Targeting retroviral and virus-like particles for gene and protein delivery$630,341
R35 · FY2018 · GM · contact PI
Interactions of MuLV IN with host proteins and DNA$376,830
R01 · FY2017 · GM · contact PI
Targeting retroviral and virus-like particles for gene and protein delivery$332,691
R35 · FY2017 · GM · contact PI
MuLV p12 function in tethering & integration$295,661
R01 · FY2017 · GM · contact PI
Interactions of MuLV IN with host proteins and DNA$376,830
R01 · FY2016 · GM · contact PI
MuLV p12 function in tethering & integration$295,661
R01 · FY2016 · GM · contact PI
Targeted delivery of Cas9/gRNA directed to HIV latent/persistent cells$198,750
R21 · FY2016 · AI · contact PI
MuLV p12 function in tethering & integration$295,661
R01 · FY2015 · GM · contact PI
Targeted delivery of Cas9/gRNA directed to HIV latent/persistent cells$232,600
R21 · FY2015 · AI · contact PI
MuLV p12 function in tethering & integration$285,348
R01 · FY2014 · GM · contact PI
Integration of Murine Retroviral Vectors$288,612
R01 · FY2013 · GM · contact PI
Integration of Murine Retroviral Vectors$293,436
R01 · FY2012 · GM · contact PI
Retroviral Integration & HDAC inhibitors$238,475
R01 · FY2012 · GM · contact PI
Retroviral Integration & HDAC inhibitors$87,106
R01 · FY2012 · GM · contact PI
Retroviral Integration & HDAC inhibitors$321,081
R01 · FY2011 · GM · contact PI
Integration of Murine Retroviral Vectors$293,436
R01 · FY2011 · GM · contact PI
Targeting Entry of Retroviral/Lentiviral Vectors$159,382
R01 · FY2011 · CA · contact PI
Targeting Entry of Retroviral/Lentiviral Vectors$118,451
R01 · FY2011 · CA · contact PI
Targeting Entry of Retroviral/Lentiviral Vectors$61,330
R01 · FY2011 · CA · contact PI
Retroviral Integration & HDAC inhibitors$315,010
R01 · FY2010 · GM · contact PI
Integration of Murine Retroviral Vectors$287,888
R01 · FY2010 · GM · contact PI
Targeting Entry of Retroviral/Lentiviral Vectors$286,425
R01 · FY2010 · CA · contact PI
Retroviral Integration & HDAC inhibitors$311,136
R01 · FY2009 · GM · contact PI
Targeting Entry of Retroviral/Lentiviral Vectors$286,425
R01 · FY2009 · CA · contact PI
Targeting Entry of Retroviral/Lentiviral Vectors$24,841
R01 · FY2009 · CA · contact PI
Targeting Entry of Retroviral/Lentiviral Vectors$286,425
R01 · FY2008 · CA · contact PI
Integration of Murine Retroviral Vectors$208,999
R01 · FY2008 · GM · contact PI
Integration of Murine Retroviral Vectors$31,244
R01 · FY2008 · GM · contact PI
Envelope Gene Products of Feline Leukemia Virus$274,237
R01 · FY2007 · CA · contact PI
Integration of Murine Retroviral Vectors$208,999
R01 · FY2007 · GM · contact PI
Envelope Gene Products of Feline Leukemia Virus$282,428
R01 · FY2006 · CA · contact PI
Integration of Murine Retroviral Vectors$215,241
R01 · FY2006 · GM · contact PI
Envelope Gene Products of Feline Leukemia Virus$289,225
R01 · FY2005 · CA
Integration of Murine Retroviral Vectors$240,671
R01 · FY2005 · GM
Integration of Murine Retroviral Vectors$19,500
R01 · FY2005 · GM
Envelope Gene Products of Feline Leukemia Virus$289,225
R01 · FY2004 · CA
Envelope Gene Products of Feline Leukemia Virus$278,009
R01 · FY2003 · CA
RETROVIRAL REVERSE TRANSCRIPTION/PREINTEGRATIVE EVENTS$222,320
R01 · FY2003 · CA
RETROVIRAL REVERSE TRANSCRIPTION/PREINTEGRATIVE EVENTS$222,320
R01 · FY2002 · CA
Targeted Retroviral Vectors for Gene Therapy of Diabetes$157,000
R21 · FY2002 · DK
ENVELOPE GENE PRODUCTS OF MURINE LEUKEMIA VIRUS$55,659
R01 · FY2002 · CA
RETROVIRAL REVERSE TRANSCRIPTION/PREINTEGRATIVE EVENTS$222,320
R01 · FY2001 · CA
Targeted Retroviral Vectors for Gene Therapy of Diabetes$157,000
R21 · FY2001 · DK
ENVELOPE GENE PRODUCTS OF MURINE LEUKEMIA VIRUS$264,140
R01 · FY2000 · CA
MECHANISM OF RETROVIRAL INTEGRATION$242,106
R01 · FY2000 · CA
RETROVIRAL REVERSE TRANSCRIPTION/PREINTEGRATIVE EVENTS$225,398
R01 · FY2000 · CA